Amily, France
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Phase
3Span
108 weeksSponsor
Karuna TherapeuticsIizuka, Fukuoka
Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Phase
1/2Span
360 weeksSponsor
Bristol-Myers SquibbIizuka, Fukuoka
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Phase
3Span
217 weeksSponsor
Karuna TherapeuticsIizuka, Fukuoka
Recruiting
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
This study has 2 parts and a 12-week (about 3 months) Follow-up Period for all participants - Part A is an open-label treatment period lasting up to 24 weeks (up to 6 months). "Open-label" means that you and the study doctors and the staff staff will know that you are taking the study drug - Part C is an open-label extended treatment period lasting up to 28 weeks (about 7 months). "Extended Treatment Period" means that you will take the study drug for 28 weeks if you are eligible to take part in this part of the study
Phase
2Span
203 weeksSponsor
Regeneron PharmaceuticalsIizuka, Fukuoka
Recruiting
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Phase
3Span
155 weeksSponsor
Kringle Pharma, Inc.Iizuka, Fukuoka
Recruiting
1-5 of 5